help button home button Am J Pathol Underwater digital camera with your antibody orders
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Purchase Article
Right arrow View Shopping Cart
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Lasota, J.
Right arrow Articles by Miettinen, M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Lasota, J.
Right arrow Articles by Miettinen, M.
(American Journal of Pathology. 1999;154:53-60.)
© 1999 American Society for Investigative Pathology

Short Communications

Mutations in Exon 11 of c-Kit Occur Preferentially in Malignant versus Benign Gastrointestinal Stromal Tumors and Do Not Occur in Leiomyomas or Leiomyosarcomas

Jerzy Lasota* , Marek Jasinski* , Maarit Sarlomo-Rikala{dagger} and Markku Miettinen*

From the Department of Soft Tissue Pathology,* Armed Forces Institute of Pathology, Washington, DC, and the 2 Department of Pathology,{dagger} Haartman Institute of the University of Helsinki, Helsinki, Finland

Gastrointestinal stromal tumors (GISTs) comprise the largest subset of mesenchymal tumors of the gastrointestinal tract. These neoplasms differ histologically and immunohistochemically from typical leiomyomas and leiomyosarcomas. Most GISTs express CD34 and CD117 (c-kit protein) but not desmin. Recently, gain-of-function mutations of c-kit proto-oncogene have been shown in five solitary GISTs and in tumors and leukocytes from a family with multiple GISTs. An in-frame deletion or a point mutation in exon 11 of c-kit was detected in these cases. Stable transfection of the mutant c-kit complementary DNA was also shown to induce malignant transformation of murine lymphoid cells, suggesting that the c-kit mutations contribute to tumor development. In this study, we evaluated 43 GISTs and 14 smooth muscle tumors for mutations in the exon 11 of c-kit by a PCR-assay. Half of the malignant GISTs (12/24) and only one benign GIST (1/19) revealed mutant bands. No mutant bands were found in 3 leiomyomas and 11 leiomyosarcomas. Sequence analysis confirmed the presence of an in-frame deletion of 3–21 bp in all 13 GISTs with mutant bands. Wild-type bands from 8 malignant and 11 benign GISTs and 7 smooth muscle tumors without mutant bands were cloned and sequenced. Additional mutations were found in 3 malignant and 2 benign GISTs. There were no mutations in 3 leiomyomas and 4 leiomyosarcomas. The mutation status of exon 11 did not correlate with immunohistochemically detectable expression of the CD117, as virtually all GISTs with or without such mutations showed CD117 immunoreactivity. The c-kit mutations occur preferentially in malignant GISTs and might be a clinically useful adjunct marker in the evaluation of GISTs. The conservation of the c-kit mutation pattern, observed in consecutive lesions from the same patients, suggests that these mutations might be useful tumor markers in monitoring recurrence or minimal residual disease.




This article has been cited by other articles:


Home page
 Clin. Cancer Res.Home page
S. Tabone-Eglinger, F. Subra, H. El Sayadi, L. Alberti, E. Tabone, J.-P. Michot, N. Theou-Anton, A. Lemoine, J.-Y. Blay, and J.-F. Emile
KIT Mutations Induce Intracellular Retention and Activation of an Immature Form of the KIT Protein in Gastrointestinal Stromal Tumors
Clin. Cancer Res., April 15, 2008; 14(8): 2285 - 2294.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
Y. Suehara, T. Kondo, K. Seki, T. Shibata, K. Fujii, M. Gotoh, T. Hasegawa, Y. Shimada, M. Sasako, T. Shimoda, et al.
Pfetin as a Prognostic Biomarker of Gastrointestinal Stromal Tumors Revealed by Proteomics
Clin. Cancer Res., March 15, 2008; 14(6): 1707 - 1717.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
J. Desai, S. Shankar, M. C. Heinrich, J. A. Fletcher, C. D. Fletcher, J. Manola, J. A. Morgan, C. L. Corless, S. George, K. Tuncali, et al.
Clonal Evolution of Resistance to Imatinib in Patients with Metastatic Gastrointestinal Stromal Tumors
Clin. Cancer Res., September 15, 2007; 13(18): 5398 - 5405.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
J.-Y. Blay, A. Le Cesne, I. Ray-Coquard, B. Bui, F. Duffaud, C. Delbaldo, A. Adenis, P. Viens, M. Rios, E. Bompas, et al.
Prospective Multicentric Randomized Phase III Study of Imatinib in Patients With Advanced Gastrointestinal Stromal Tumors Comparing Interruption Versus Continuation of Treatment Beyond 1 Year: The French Sarcoma Group
J. Clin. Oncol., March 20, 2007; 25(9): 1107 - 1113.
[Abstract] [Full Text] [PDF]

Home page
 J. Mol. Diagn.Home page
J. Lasota, B. Wasag, S. E. Steigen, J. Limon, and M. Miettinen
Improved Detection of KIT Exon 11 Duplications in Formalin-Fixed, Paraffin-Embedded Gastrointestinal Stromal Tumors
J. Mol. Diagn., February 1, 2007; 9(1): 89 - 94.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
P. Schurr, S. Wolter, J. Kaifi, U. Reichelt, H. Kleinhans, R. Wachowiak, E. Yekebas, T. Strate, V. Kalinin, R. Simon, et al.
Microsatellite DNA Alterations of Gastrointestinal Stromal Tumors Are Predictive for Outcome
Clin. Cancer Res., September 1, 2006; 12(17): 5151 - 5157.
[Abstract] [Full Text] [PDF]

Home page
 J. Clin. Pathol.Home page
L Tornillo and L M Terracciano
An update on molecular genetics of gastrointestinal stromal tumours.
J. Clin. Pathol., June 1, 2006; 59(6): 557 - 563.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
C. Reindl, K. Bagrintseva, S. Vempati, S. Schnittger, J. W. Ellwart, K. Wenig, K.-P. Hopfner, W. Hiddemann, and K. Spiekermann
Point mutations in the juxtamembrane domain of FLT3 define a new class of activating mutations in AML
Blood, May 1, 2006; 107(9): 3700 - 3707.
[Abstract] [Full Text] [PDF]

Home page
 Jpn J Clin OncolHome page
S. Kondo, U. Yamaguchi, S. Sakurai, Y. Ikezawa, H. Chuman, U. Tateishi, K. Furuta, and T. Hasegawa
Cytogenetic Confirmation of a Gastrointestinal Stromal Tumor and Ewing Sarcoma/Primitive Neuroectodermal Tumor in a Single Patient
Jpn. J. Clin. Oncol., December 1, 2005; 35(12): 753 - 756.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
N. Theou, S. Gil, A. Devocelle, C. Julie, A. Lavergne-Slove, A. Beauchet, P. Callard, R. Farinotti, A. Le Cesne, A. Lemoine, et al.
Multidrug Resistance Proteins in Gastrointestinal Stromal Tumors: Site-Dependent Expression and Initial Response to Imatinib
Clin. Cancer Res., November 1, 2005; 11(21): 7593 - 7598.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
J. Martin, A. Poveda, A. Llombart-Bosch, R. Ramos, J. A. Lopez-Guerrero, J. G. del Muro, J. Maurel, S. Calabuig, A. Gutierrez, J. L. G. de Sande, et al.
Deletions Affecting Codons 557-558 of the c-KIT Gene Indicate a Poor Prognosis in Patients With Completely Resected Gastrointestinal Stromal Tumors: A Study by the Spanish Group for Sarcoma Research (GEIS)
J. Clin. Oncol., September 1, 2005; 23(25): 6190 - 6198.
[Abstract] [Full Text] [PDF]

Home page
 J. Clin. Pathol.Home page
R Penzel, S Aulmann, M Moock, M Schwarzbach, R J Rieker, and G Mechtersheimer
The location of KIT and PDGFRA gene mutations in gastrointestinal stromal tumours is site and phenotype associated
J. Clin. Pathol., June 1, 2005; 58(6): 634 - 639.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
F. P. Li, J. A. Fletcher, M. C. Heinrich, J. E. Garber, S. E. Sallan, C. Curiel-Lewandrowski, A. Duensing, M. van de Rijn, L. E. Schnipper, and G. D. Demetri
Familial Gastrointestinal Stromal Tumor Syndrome: Phenotypic and Molecular Features in a Kindred
J. Clin. Oncol., April 20, 2005; 23(12): 2735 - 2743.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
H. Sihto, M. Sarlomo-Rikala, O. Tynninen, M. Tanner, L. C. Andersson, K. Franssila, N. N. Nupponen, and H. Joensuu
KIT and Platelet-Derived Growth Factor Receptor Alpha Tyrosine Kinase Gene Mutations and KIT Amplifications in Human Solid Tumors
J. Clin. Oncol., January 1, 2005; 23(1): 49 - 57.
[Abstract] [Full Text] [PDF]

Home page
 INT J SURG PATHOLHome page
O. Daum, T. Vanecek, R. Sima, R. Curik, M. Zamecnik, S. Yamanaka, P. Mukensnabl, Z. Benes, and M. Michal
Reactive Nodular Fibrous Pseudotumors of the Gastrointestinal Tract: Report of 8 Cases
International Journal of Surgical Pathology, October 1, 2004; 12(4): 365 - 374.
[Abstract] [PDF]

Home page
 JCOHome page
C. L. Corless, J. A. Fletcher, and M. C. Heinrich
Biology of Gastrointestinal Stromal Tumors
J. Clin. Oncol., September 15, 2004; 22(18): 3813 - 3825.
[Abstract] [Full Text] [PDF]

Home page
 IOVSHome page
C. All-Ericsson, L. Girnita, A. Muller-Brunotte, B. Brodin, S. Seregard, A. Ostman, and O. Larsson
c-Kit-Dependent Growth of Uveal Melanoma Cells: A Potential Therapeutic Target?
Invest. Ophthalmol. Vis. Sci., July 1, 2004; 45(7): 2075 - 2082.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
L. Boldrini, S. Ursino, S. Gisfredi, P. Faviana, V. Donati, T. Camacci, M. Lucchi, A. Mussi, F. Basolo, R. Pingitore, et al.
Expression and Mutational Status of c-kit in Small-Cell Lung Cancer: Prognostic Relevance
Clin. Cancer Res., June 15, 2004; 10(12): 4101 - 4108.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
C. R. Antonescu, A. Viale, L. Sarran, S. J. Tschernyavsky, M. Gonen, N. H. Segal, R. G. Maki, N. D. Socci, R. P. DeMatteo, and P. Besmer
Gene Expression in Gastrointestinal Stromal Tumors Is Distinguished by KIT Genotype and Anatomic Site
Clin. Cancer Res., May 15, 2004; 10(10): 3282 - 3290.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
M. R. Raspollini, G. Amunni, A. Villanucci, P. Pinzani, L. Simi, M. Paglierani, and G. L. Taddei
c-Kit Expression in Patients with Uterine Leiomyosarcomas: A Potential Alternative Therapeutic Treatment
Clin. Cancer Res., May 15, 2004; 10(10): 3500 - 3503.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
T. Kindler, F. Breitenbuecher, A. Marx, J. Beck, G. Hess, B. Weinkauf, J. Duyster, C. Peschel, C. J. Kirkpatrick, M. Theobald, et al.
Efficacy and safety of imatinib in adult patients with c-kit-positive acute myeloid leukemia
Blood, May 15, 2004; 103(10): 3644 - 3654.
[Abstract] [Full Text] [PDF]

Home page
 Ann. Surg. Oncol.Home page
B. L. Eisenberg and I. Judson
Surgery and Imatinib in the Management of GIST: Emerging Approaches to Adjuvant and Neoadjuvant Therapy
Ann. Surg. Oncol., May 1, 2004; 11(5): 465 - 475.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
T. W. Kim, H. Lee, Y.-K. Kang, M. S. Choe, M.-H. Ryu, H. M. Chang, J. S. Kim, J. H. Yook, B. S. Kim, and J. S. Lee
Prognostic Significance of c-kit Mutation in Localized Gastrointestinal Stromal Tumors
Clin. Cancer Res., May 1, 2004; 10(9): 3076 - 3081.
[Abstract] [Full Text] [PDF]

Home page
 JNMHome page
G. Antoch, J. Kanja, S. Bauer, H. Kuehl, K. Renzing-Koehler, J. Schuette, A. Bockisch, J. F. Debatin, and L. S. Freudenberg
Comparison of PET, CT, and Dual-Modality PET/CT Imaging for Monitoring of Imatinib (STI571) Therapy in Patients with Gastrointestinal Stromal Tumors
J. Nucl. Med., March 1, 2004; 45(3): 357 - 365.
[Abstract] [Full Text]

Home page
 Clin. Cancer Res.Home page
M. E. Robson, E. Glogowski, G. Sommer, C. R. Antonescu, K. Nafa, R. G. Maki, N. Ellis, P. Besmer, M. Brennan, and K. Offit
Pleomorphic Characteristics of a Germ-Line KIT Mutation in a Large Kindred with Gastrointestinal Stromal Tumors, Hyperpigmentation, and Dysphagia
Clin. Cancer Res., February 15, 2004; 10(4): 1250 - 1254.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
M. C. Heinrich, C. L. Corless, G. D. Demetri, C. D. Blanke, M. von Mehren, H. Joensuu, L. S. McGreevey, C.-J. Chen, A. D. Van den Abbeele, B. J. Druker, et al.
Kinase Mutations and Imatinib Response in Patients With Metastatic Gastrointestinal Stromal Tumor
J. Clin. Oncol., December 1, 2003; 21(23): 4342 - 4349.
[Abstract] [Full Text] [PDF]

Home page
 Molecular Cancer TherapeuticsHome page
A. Frolov, S. Chahwan, M. Ochs, J. P. Arnoletti, Z.-Z. Pan, O. Favorova, J. Fletcher, M. von Mehren, B. Eisenberg, and A. K. Godwin
Response Markers and the Molecular Mechanisms of Action of Gleevec in Gastrointestinal Stromal Tumors
Mol. Cancer Ther., August 1, 2003; 2(8): 699 - 709.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
C. R. Antonescu, G. Sommer, L. Sarran, S. J. Tschernyavsky, E. Riedel, J. M. Woodruff, M. Robson, R. Maki, M. F. Brennan, M. Ladanyi, et al.
Association of KIT Exon 9 Mutations with Nongastric Primary Site and Aggressive Behavior: KIT Mutation Analysis and Clinical Correlates of 120 Gastrointestinal Stromal Tumors
Clin. Cancer Res., August 1, 2003; 9(9): 3329 - 3337.
[Abstract] [Full Text] [PDF]

Home page
 INT J SURG PATHOLHome page
J. Rosai
GIST: An Update
International Journal of Surgical Pathology, July 1, 2003; 11(3): 177 - 186.
[PDF]

Home page
 JCOHome page
K. Scotlandi, M. C. Manara, R. Strammiello, L. Landuzzi, S. Benini, S. Perdichizzi, M. Serra, A. Astolfi, G. Nicoletti, P.-L. Lollini, et al.
c-kit Receptor Expression in Ewing's Sarcoma: Lack of Prognostic Value but Therapeutic Targeting Opportunities in Appropriate Conditions
J. Clin. Oncol., May 15, 2003; 21(10): 1952 - 1960.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
Y. R. Choi, H. Kim, H. J. Kang, N.-G. Kim, J. J. Kim, K.-S. Park, Y.-K. Paik, H. O. Kim, and H. Kim
Overexpression of High Mobility Group Box 1 in Gastrointestinal Stromal Tumors with KIT Mutation
Cancer Res., May 1, 2003; 63(9): 2188 - 2193.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
R. Schneider-Stock, C. Boltze, J. Lasota, M. Miettinen, B. Peters, M. Pross, A. Roessner, and T. Gunther
High Prognostic Value of p16INK4 Alterations in Gastrointestinal Stromal Tumors
J. Clin. Oncol., May 1, 2003; 21(9): 1688 - 1697.
[Abstract] [Full Text] [PDF]

Home page
 J. Clin. Pathol.Home page
T Tornoczky, E Kover, and L Pajor
Frequent occurrence of low grade cases among metastatic gastrointestinal stromal tumours
J. Clin. Pathol., May 1, 2003; 56(5): 363 - 367.
[Abstract] [Full Text] [PDF]

Home page
 J Oncol Pharm PractHome page
A. Hole and D. Blake
A review of imatinib mesilate in the treatment of patients with gastrointestinal stromal tumours and chronic myeloid leukaemia
Journal of Oncology Pharmacy Practice, March 1, 2003; 9(1): 1 - 14.
[Abstract] [PDF]

Home page
 Vet PatholHome page
D. Frost, J. Lasota, and M. Miettinen
Gastrointestinal Stromal Tumors and Leiomyomas in the Dog: A Histopathologic, Immunohistochemical, and Molecular Genetic Study of 50 Cases
Vet. Pathol., January 1, 2003; 40(1): 42 - 54.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Roentgenol.Home page
T. Nishida, S. Kumano, T. Sugiura, H. Ikushima, K. Nishikawa, T. Ito, and H. Matsuda
Multidetector CT of High-Risk Patients with Occult Gastrointestinal Stromal Tumors
Am. J. Roentgenol., January 1, 2003; 180(1): 185 - 189.
[Abstract] [Full Text] [PDF]

Home page
 The OncologistHome page
D. P. Ryan, T. Puchalski, J. G. Supko, D. Harmon, R. Maki, R. Garcia-Carbonero, C. Kuhlman, J. Winkelman, P. Merriam, T. Quigley, et al.
A Phase II and Pharmacokinetic Study of Ecteinascidin 743 in Patients with Gastrointestinal Stromal Tumors
Oncologist, December 1, 2002; 7(6): 531 - 538.
[Abstract] [Full Text] [PDF]

Home page
 Ann. Surg. Oncol.Home page
R. P. DeMatteo
The GIST of Targeted Cancer Therapy: A Tumor (Gastrointestinal Stromal Tumor), a Mutated Gene (c-kit), and a Molecular Inhibitor (STI571)
Ann. Surg. Oncol., November 1, 2002; 9(9): 831 - 839.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
R. Dagher, M. Cohen, G. Williams, M. Rothmann, J. Gobburu, G. Robbie, A. Rahman, G. Chen, A. Staten, D. Griebel, et al.
Approval Summary: Imatinib Mesylate in the Treatment of Metastatic and/or Unresectable Malignant Gastrointestinal Stromal Tumors
Clin. Cancer Res., October 1, 2002; 8(10): 3034 - 3038.
[Abstract] [Full Text] [PDF]

Home page
 Molecular Cancer TherapeuticsHome page
M. J. Frost, P. T. Ferrao, T. P. Hughes, and L. K. Ashman
Juxtamembrane Mutant V560GKit Is More Sensitive to Imatinib (STI571) Compared with Wild-Type c-Kit Whereas the Kinase Domain Mutant D816VKit Is Resistant
Mol. Cancer Ther., October 1, 2002; 1(12): 1115 - 1124.
[Abstract] [Full Text] [PDF]

Home page
 The OncologistHome page
M. H. Cohen, R. Dagher, D. J. Griebel, A. Ibrahim, A. Martin, N. S. Scher, G. H. Sokol, G. A. Williams, and R. Pazdur
U.S. Food and Drug Administration Drug Approval Summaries: Imatinib Mesylate, Mesna Tablets, and Zoledronic Acid
Oncologist, October 1, 2002; 7(5): 393 - 400.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
S. Singer, B. P. Rubin, M. L. Lux, C.-J. Chen, G. D. Demetri, C. D.M. Fletcher, and J. A. Fletcher
Prognostic Value of KIT Mutation Type, Mitotic Activity, and Histologic Subtype in Gastrointestinal Stromal Tumors
J. Clin. Oncol., September 15, 2002; 20(18): 3898 - 3905.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Pathol.Home page
J. A. Fletcher, C. D.M. Fletcher, B. P. Rubin, L. K. Ashman, C. L. Corless, M. C. Heinrich, J. Andersson, H. Sjogren, J. Meis-Kindblom, G. Stenman, et al.
KIT Gene Mutations in Gastrointestinal Stromal Tumors : More Complex than Previously Recognized?
Am. J. Pathol., August 1, 2002; 161(2): 737 - 739.
[Full Text] [PDF]

Home page
 Am. J. Pathol.Home page
C. L. Corless, L. McGreevey, A. Haley, A. Town, and M. C. Heinrich
KIT Mutations Are Common in Incidental Gastrointestinal Stromal Tumors One Centimeter or Less in Size
Am. J. Pathol., May 1, 2002; 160(5): 1567 - 1572.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
M. C. Heinrich, C. D. Blanke, B. J. Druker, and C. L. Corless
Inhibition of KIT Tyrosine Kinase Activity: A Novel Molecular Approach to the Treatment of KIT-Positive Malignancies
J. Clin. Oncol., March 15, 2002; 20(6): 1692 - 1703.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
V. H. C. Bramwell, D. Morris, D. S. Ernst, I. Hings, M. Blackstein, P. M. Venner, E. I. Ette, M. W. Harding, A. Waxman, and G. D. Demetri
Safety and Efficacy of the Multidrug-Resistance Inhibitor Biricodar (VX-710) with Concurrent Doxorubicin in Patients with Anthracycline-resistant Advanced Soft Tissue Sarcoma
Clin. Cancer Res., February 1, 2002; 8(2): 383 - 393.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Pathol.Home page
J. Andersson, H. Sjogren, J. M. Meis-Kindblom, G. Stenman, P. Aman, and L.-G. Kindblom
The Complexity of KIT Gene Mutations and Chromosome Rearrangements and Their Clinical Correlation in Gastrointestinal Stromal (Pacemaker Cell) Tumors
Am. J. Pathol., January 1, 2002; 160(1): 15 - 22.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
B. P. Rubin, S. Singer, C. Tsao, A. Duensing, M. L. Lux, R. Ruiz, M. K. Hibbard, C.-J. Chen, S. Xiao, D. A. Tuveson, et al.
KIT Activation Is a Ubiquitous Feature of Gastrointestinal Stromal Tumors
Cancer Res., November 1, 2001; 61(22): 8118 - 8121.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Chem.Home page
Z.-M. Sheng, R. M. Przygodzki, and T. J. O'Leary
Rapid Screening for KIT Mutations by Capillary Electrophoresis
Clin. Chem., July 1, 2001; 47(7): 1325 - 1326.
[Full Text] [PDF]

Home page
 NEJMHome page
H. Joensuu, P. J. Roberts, M. Sarlomo-Rikala, L. C. Andersson, P. Tervahartiala, D. Tuveson, S. L. Silberman, R. Capdeville, S. Dimitrijevic, B. Druker, et al.
Effect of the Tyrosine Kinase Inhibitor STI571 in a Patient with a Metastatic Gastrointestinal Stromal Tumor
N. Engl. J. Med., April 5, 2001; 344(14): 1052 - 1056.
[Full Text] [PDF]

Home page
 J. Clin. Pathol.Home page
J F G. van Roggen, M L F van Velthuysen, and P C W Hogendoorn
The histopathological differential diagnosis of gastrointestinal stromal tumours
J. Clin. Pathol., February 1, 2001; 54(2): 96 - 102.
[Abstract] [Full Text] [PDF]

Home page
 Ann. Surg. Oncol.Home page
J. A. Crosby, C. N. Catton, A. Davis, J. Couture, B. O'Sullivan, R. Kandel, and C. J. Swallow
Malignant Gastrointestinal Stromal Tumors of the Small Intestine: A Review of 50 Cases From a Prospective Database
Ann. Surg. Oncol., January 1, 2001; 8(1): 50 - 59.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Pathol.Home page
K. Isozaki, B. Terris, J. Belghiti, S. Schiffmann, S. Hirota, and J.-M. Vanderwinden
Germline-Activating Mutation in the Kinase Domain of KIT Gene in Familial Gastrointestinal Stromal Tumors
Am. J. Pathol., November 1, 2000; 157(5): 1581 - 1585.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Pathol.Home page
J. Lasota, A. Wozniak, M. Sarlomo-Rikala, J. Rys, R. Kordek, A. Nassar, L. H. Sobin, and M. Miettinen
Mutations in Exons 9 and 13 of KIT Gene Are Rare Events in Gastrointestinal Stromal Tumors : A Study of 200 Cases
Am. J. Pathol., October 1, 2000; 157(4): 1091 - 1095.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
B. E. C. Plaat, H. Hollema, W. M. Molenaar, G. H. T. Broers, J. Pijpe, M. F. Mastik, H. J. Hoekstra, E. van den Berg, R. J. Scheper, and W. T. A. van der Graaf
Soft Tissue Leiomyosarcomas and Malignant Gastrointestinal Stromal Tumors: Differences in Clinical Outcome and Expression of Multidrug Resistance Proteins
J. Clin. Oncol., September 18, 2000; 18(18): 3211 - 3220.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
M. C. Heinrich, D. J. Griffith, B. J. Druker, C. L. Wait, K. A. Ott, and A. J. Zigler
Inhibition of c-kit receptor tyrosine kinase activity by STI 571, a selective tyrosine kinase inhibitor
Blood, August 1, 2000; 96(3): 925 - 932.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Pathol.Home page
T. L. Robinson, K. Sircar, B. R. Hewlett, K. Chorneyko, R. H. Riddell, and J. D. Huizinga
Gastrointestinal Stromal Tumors May Originate from a Subset of CD34-Positive Interstitial Cells of Cajal
Am. J. Pathol., April 1, 2000; 156(4): 1157 - 1163.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Pathol.Home page
M. L. Lux, B. P. Rubin, T. L. Biase, C.-J. Chen, T. Maclure, G. Demetri, S. Xiao, S. Singer, C. D.M. Fletcher, and J. A. Fletcher
KIT Extracellular and Kinase Domain Mutations in Gastrointestinal Stromal Tumors
Am. J. Pathol., March 1, 2000; 156(3): 791 - 795.
[Abstract] [Full Text] [PDF]

Home page
 INT J SURG PATHOLHome page
B. P. Rubin, J. A. Fletcher, and C. D. M. Fletcher
Molecular Insights into the Histogenesis and Pathogenesis of Gastrointestinal Stromal Tumors
International Journal of Surgical Pathology, January 1, 2000; 8(1): 5 - 10.
[Abstract] [PDF]

Home page
 Cancer Res.Home page
M. Taniguchi, T. Nishida, S. Hirota, K. Isozaki, T. Ito, T. Nomura, H. Matsuda, and Y. Kitamura
Effect of c-kit Mutation on Prognosis of Gastrointestinal Stromal Tumors
Cancer Res., September 1, 1999; 59(17): 4297 - 4300.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK